Comments
Biocon’s scrip today gained nearly 6 per cent after the company announced a global partnership with Sandoz, a Novartis division, to develop, manufacture and commercialise multiple biosimilars in immunology and oncology for patients worldwide.
The stock jumped 5.61 per cent to end at Rs 569.85 on the BSE. During the day, it rose 6.61 per cent to Rs 575.30 -- its 52-week high. On the NSE, shares of the company went up by 5.51 per cent to close at Rs 569.35. In terms of equity volume, 8.72 lakh shares of the company were traded on the BSE and over 87 lakh shares changed hands on the NSE during the day.
Under the terms of the agreement, both companies will share the responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products and will have a cost and profit share arrangement globally, Biocon had said in a statement yesterday.
Worldwide commercialisation responsibilities will be divided and each company’s strengths will be leveraged within specific geographies, it added.
Sandoz will lead commercialisation in North America (US and Canada) and the EU, including European Free Trade Association and Balkan states, while Biocon will lead commercialisation in rest of the world, including India, Russia and Commonwealth of Independent States (CIS), Biocon said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.